Thermoreversible in situ gelling poloxamer-based systems with chitosan nanocomplexes for prolonged subcutaneous delivery of heparin: Design and in vitro evaluation

European Journal of Pharmaceutical Sciences

Volumn 50, Issue 1, 2013, Pages 93-101

  Radivojša, Maja ^a   Grabnar, Iztok ^a   Grabnar, Pegi Ahlin ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Chitosan nanocomplexes; Heparin; In situ forming systems; Prolonged release; Subcutaneous delivery; Thermoreversible hydrogels

Indexed keywords

CHITOSAN; HEPARIN; HYDROXYPROPYLMETHYLCELLULOSE; POLOXAMER;

ARTICLE; DELAYED DRUG RELEASE; DRUG DELIVERY SYSTEM; GELATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE; VISCOSITY; ZETA POTENTIAL;

EID: 84885076799     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.03.002     Document Type: Article

References (37)

1. Alexandridis, P., Hatton, T.A., 1995. Poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. Colloids Surf. A 96, 1-46.
2. Barichello, J.M., Morishita, M., Takayama, K., Nagai, T., 1999. Absorption of insulin from Pluronic F-127 gels following subcutaneous administration in rats. Int. J. Pharm. 184, 189-198. (Pubitemid 29317652)
3. Bermudez, J.M., Grau, R., 2011. Thermosensitive poloxamer-based injectables as controlled drug release platforms for veterinary use: Development and in-vitro evaluation. Int. Res. J. Pharm. Pharmacol. 1, 109-118.
4. Boddohi, S., Moore, N., Johnson, A.P., Matt, J.K., 2009. Polysaccharide-based polyelectrolyte complex nanoparticles from chitosan, heparin, and hyaluronan. Biomacromolecules 10, 1402-1409.
5. Cafaggi, S., Russo, E., Caviglioli, G., Parodi, B., Stefani, R., Sillo, G., Leardi, R., Bignardi, G., 2008. Poloxamer 407 as a solubilising agent for tolfenamic acid and as a base for a gel formulation. Eur. J. Pharm. Sci. 35, 19-29.
6. Chen, M.C., Wong, H.S., Lin, K.J., Chen, H.L., Wey, S.P., Sonaje, K., Lin, Y.H., Chu, C.Y., Sung, H.W., 2009. The characteristics, biodistribution and bioavailability of a chitosan-based nanoparticulate system for the oral delivery of heparin. Biomaterials 30, 6629-6637.
7. Chung, Y.-I., Lee, S.-Y., Tae, G., 2006. The effect of heparin on the gelation of Pluronic F-127 hydrogel. Colloids Surf. A: Physicochem. Eng. Asp. 284-285, 480-484. (Pubitemid 43850705)
8. Dalmoro, A., Barba, A.A., Lamberti, G., Grassi, M., D'Amore, M., 2012. Pharmaceutical applications of biocompatible polymer blends containing sodium alginate. Adv. Polym. Technol. 31 (3), 219-230.
9. Dumortier, G., Grossiord, J.L., Agnely, F., Chaumeil, J.C., 2006. A review of poloxamer 407 pharmaceutical and pharmacological characteristics. Pharm. Res. 23, 2709-2728. (Pubitemid 44885361)
10. Escobar-Chavez, J.J., Lopez-Cervantes, M., Naik, A., Kalia, Y.N., Quintanar-Guerrero, D., Ganem-Quintanar, A., 2006. Applications of thermoreversible pluronic F-127 gels in pharmaceutical formulations. J. Pharm. Sci 9, 339-358. (Pubitemid 46655458)
11. Gilbert, J.C., Hadgraft, J., Bye, A., Brookes, L.G., 1986. Drug release from Pluronic F-127 gels. Int. J. Pharm. 32, 223-228. (Pubitemid 16015303)
12. Gombotz, W.R., Pettit, D.K., 1995. Biodegradable polymers for protein and peptide drug delivery. Bioconjug. Chem. 6, 332-351.
13. Grassi, G., Farra, R., Noro, E., Voinovich, D., Lapasin, R., Dapas, B., Alpar, O., Zennaro, C., Carraro, M., Giansante, C., Guarnieri, G., Pascotto, A., Rehimers, B., Grassi, M., 2007. Characterization of nucleic acid molecule/liposome complexes and rheological effects on pluronic/alginate matrices. J. Drug Deliv. Sci. Technol. 17 (5), 325-331. (Pubitemid 350099988)
14. Hejazi, R., Amiji, M., 2003. Chitosan-based gastrointestinal delivery systems. J. Control. Release 89, 151-165. (Pubitemid 36507012)
15. Hirsh, J., Warkentin, T.E., Raschke, R., Granger, C., Ohman, E.M., Dalen, J.E., 1998. Heparin and low-molecular-weight heparin mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 114, 489S-510S. (Pubitemid 28535777)
16. Hoffart, V., Lamprecht, A., Maincent, P., Lecompte, T., Vigneron, C., Ubrich, N., 2006. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J. Control. Release 113, 38-42. (Pubitemid 43818166)
17. Illum, L., Jabbal-Gill, I., Hinchcliffe, M., Fisher, A.N., Davis, S.S., 2001. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev. 51, 81-96. (Pubitemid 32763074)
18. Jeong, B., Kim Wan, S., Bae Han, Y., 2012. Thermosensitive sol-gel reversible hydrogels. Adv. Drug Deliv. Rev. 64, 154-162.
19. Karewicz, A., Zasada, K., Szczubialka, K., Zapotoczny, S., Lach, R., Nowakowska, M., 2010. "Smart" alginate-hydroxypropylcellulose microbeads for controlled release of heparin. Int. J. Pharm. 385, 163-169.
20. Kempe, S., Mader, K., 2012. In situ forming implants - an attractive formulation principle for parenteral depot formulations. J. Control. Release 161, 668-679.
21. Krauland, A., Alonso, M., 2007. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. Int. J. Pharm. 340, 134-142. (Pubitemid 47043346)
22. Liu, Y., Lu, W.L., Wang, H.C., Zhang, X., Zhang, H., Wang, X.Q., Zhou, T.Y., Zhang, Q., 2007. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic® F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J. Control. Release 117, 387-395. (Pubitemid 46216584)
23. Liu, Y., Zhu, Y.Y., Wei, G., Lu, W.Y., 2009. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: improved in vitro and in vivo sustained-release properties. Eur. J. Pharm. Sci. 37, 306-312.
24. Mao, S., Bakowsky, U., Jintapattanakit, A., Kissel, T., 2006. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and insulin. J. Int. Pharm. 95, 1035-1048. (Pubitemid 43723163)
25. Narasimhan, B., Peppas, N.A., 1997. Molecular analysis of drug delivery systems controlled by dissolution of the polymer carrier. J. Pharm. Sci. 86, 297-304. (Pubitemid 27113762)
26. Němcová, I., Rychlowský, P., Havelcová, M., Brabcová, M., 1999. Determination of heparin using flow injection analysis with spectrophotometric detection. Anal. Chim. Acta 401, 223-228. (Pubitemid 29516583)
27. Oliveira, G.B., Carvalho Jr., L.B., Silva, M.P.C., 2003. Properties of carbodiimide treated heparin. Biomaterials 24, 4777-4783. (Pubitemid 37188659)
28. Packhaeuser, C.B., Schnieders, J., Oster, C.G., Kissel, T., 2004. In situ forming parenteral drug delivery systems: an overview. Eur. J. Pharm. Biopharm. 58, 445-455. (Pubitemid 39037247)
29. Ruel-Gariépy, E., Leroux, J.C., 2004. In situ-forming hydrogels - review of temperature-sensitive systems. Eur. J. Pharm. Biopharm. 58, 409-426. (Pubitemid 39037244)
30. Schmolka, I.R., 1972. Artificial skin I. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6, 571-582.
31. Sharma, P.K., Bhatia, S.R., 2004. Effect of anti-inflammatories on Pluronic F127: micellar assembly, gelation and partitioning. Int. J. Pharm. 278, 361-377. (Pubitemid 38759509)
32. Sun, W., Mao, S., Mei, D., Kissel, T., 2008. Self-assembled polyelectrolyte nanocomplexes between chitosan derivatives and enoxaparin. Eur. J. Pharm. Biopharm. 69, 417-425.
33. Ulbrich, N., Maincent, P., 2005. Recent advances in heparin delivery. In: Benita, S. Microencapsulation. Methods and Industrial Applications. Informa Healthcare, pp. 481-520.
34. Ur-Rehman, T., Tavelin, S., Grobner, G., 2011. Chitosan in situ gelation for improved drug loading and retention in poloxamer 407 gels. Int. J. Pharm. 409, 19-29.
35. Wei, G., Ding, P.T., Li, S.M., Zheng, J.M., 2002. Thermosetting gels with modulated gelation temperature for ophthalmic use: the rheological and gamma scintigraphic studies. J. Control. Release 83, 65-74. (Pubitemid 35239815)
36. Xuan, J.J., Balakrishnan, P., Oh, D.H., Yeo, W.H., Park, S.M., Yong, C.S., Choi, H.G., 2010. Rheological characterization and in vivo evaluation of thermosensitive poloxamer-based hydrogel for intramuscular injection of piroxicam. Int. J. Pharm. 395, 317-323.
37. Zhang, L., Parsons, D.L., Navarre, C., 2002. Development and in-vitro evaluation of sustained release poloxamer 407 (P407) gel formulations of ceftiofur. J. Control. Release 85, 73-81. (Pubitemid 35449455)